Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites
Top Cited Papers
Open Access
- 25 May 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 52 (3), 1017-1022
- https://doi.org/10.1002/hep.23775
Abstract
Beta-blockers may have a negative impact on survival in patients with cirrhosis and refractory ascites. The aim of this study was to evaluate the effect of the administration of beta-blockers on long-term survival in patients with cirrhosis and refractory ascites. We performed a single-center, observational, case-only, prospective study of patients with cirrhosis and refractory ascites who did or did not receive beta-blockers for the prevention of gastrointestinal bleeding; 151 patients were included. The mean Model for End-Stage Liver Disease score was 18.8 ± 4.1. All patients regularly underwent large-volume paracentesis and intravenous albumin administration. Seventy-seven patients (51%) were treated with propranolol (113 ± 46 mg/day). The median follow-up for the whole group was 8 months. The median survival time was 10 months [95% confidence interval (CI) = 8-12 months]. The probability of survival at 1 year was 41% (95% CI = 33%-49%). The clinical characteristics and laboratory values at enrolment were not significantly different between patients who were receiving propranolol and those who were not. The median survival time was 20.0 months (95% CI = 4.8-35.2 months) in patients not treated with propranolol and 5.0 months (95% CI = 3.5-6.5 months) in those treated with propranolol (P = 0.0001). The 1-year probability of survival was significantly lower in patients who received propranolol [19% (95% CI = 9%-29%)] versus those who did not [64% (95% CI = 52%-76%), P < 0.0001]. The independent variables of mortality were Child-Pugh class C, hyponatremia and renal failure as causes of refractory ascites, and beta-blocker therapy. Conclusion: The use of beta-blockers is associated with poor survival in patients with refractory ascites. These results suggest that beta-blockers should be contraindicated in these patients. HEPATOLOGY 2010Keywords
This publication has 26 references indexed in Scilit:
- Hyponatremia and Mortality among Patients on the Liver-Transplant Waiting ListNew England Journal of Medicine, 2008
- Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosisHepatology, 2007
- Management of Cirrhosis and AscitesNew England Journal of Medicine, 2004
- The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites ClubHepatology, 2003
- Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot studyGut, 2002
- Updating Consensus in Portal Hypertension: Report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertensionJournal of Hepatology, 2000
- Pharmacological treatment of portal hypertension: present and futureJournal of Hepatology, 1998
- Hemodynamic changes in patients developing effective hypovolemia after total paracentesisJournal of Hepatology, 1998
- Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosisHepatology, 1996
- Peritoneovenous Shunting as Compared with Medical Treatment in Patients with Alcoholic Cirrhosis and Massive AscitesNew England Journal of Medicine, 1989